These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12591833)

  • 1. Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
    Janzon M; Levin LA; Swahn E;
    Heart; 2003 Mar; 89(3):287-92. PubMed ID: 12591833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
    Lancet; 1999 Aug; 354(9180):701-7. PubMed ID: 10475180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
    Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving outcomes in acute coronary syndromes--the FRISC II trial.
    Kontny F
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I3-7. PubMed ID: 11286312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease.
    Janzon M; Levin LA; Swahn E
    Eur Heart J; 2002 Jan; 23(1):31-40. PubMed ID: 11741360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
    Wallentin L; Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E
    Lancet; 2000 Jul; 356(9223):9-16. PubMed ID: 10892758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
    Swahn E; Wallentin L
    Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
    Wallentin L
    Haemostasis; 2000; 30 Suppl 2():108-13; discussion 106-7. PubMed ID: 11251353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
    Husted SE; Wallentin L; Lagerqvist B; Kontny F; Ståhle E; Swahn E
    Eur Heart J; 2002 Aug; 23(15):1213-8. PubMed ID: 12127923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
    Lindmarker P; Holmström M
    J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term management--the way forward?
    Wallentin L
    Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I13-7. PubMed ID: 10680039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment.
    Jernberg T; Abrahamsson P; Lindahl B; Johanson P; Wallentin L; Dellborg M
    Eur Heart J; 2002 Jul; 23(14):1093-101. PubMed ID: 12090747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalteparin for acute coronary syndromes.
    O'Loughlin DC
    Heart Dis; 1999; 1(5):329-36. PubMed ID: 11720639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.
    Lancet; 1999 Aug; 354(9180):708-15. PubMed ID: 10475181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
    Oldgren J; Fellenius C; Boman K; Jansson JH; Nilsson TK; Wallentin L; Siegbahn A
    J Intern Med; 2005 Nov; 258(5):420-7. PubMed ID: 16238677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease.
    Klein W; Buchwald A; Hillis WS; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Am J Cardiol; 1997 Sep; 80(5A):30E-34E. PubMed ID: 9296467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.
    Husted S; Becker R; Kher A
    Clin Cardiol; 2001 Jul; 24(7):492-9. PubMed ID: 11444639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
    Lindahl B; Venge P; Wallentin L
    J Am Coll Cardiol; 1997 Jan; 29(1):43-8. PubMed ID: 8996293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.